Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a highly lethal disease that exhibits a rising global incidence, and most HCC patients are at an advanced stage at the time of diagnosis. Although lenvatinib has become the first-line option for HCC and its overall survival is not inferior to sorafenib, not all HCC...
Saved in:
| Main Authors: | Xiangyong Hao, Zihan Li, Xin Su, Jian Li, Youbao Ye, Cailiu Wang, Xiao Xu, Hao Song, Baoling Song, Xiang Lan, Tian Luo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-08-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251363102 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease
by: Xiangyong Hao, et al.
Published: (2025-12-01) -
Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
by: Thaninee Prasoppokakorn, et al.
Published: (2022-01-01) -
Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation
by: Ming Zhao, et al.
Published: (2025-08-01) -
Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation
by: Yuan Yuan, et al.
Published: (2025-12-01) -
Phthalates promote lenvatinib resistance in hepatocellular carcinoma through the HPX-MAPK pathway
by: Jinlu Han, et al.
Published: (2025-09-01)